Selegiline HCl 1.25 mg Oral Capsules are a solid dosage form consisting of two halves of either gelatin or vegetarian-based shells that encapsulate the medication. This form of medication is designed to be swallowed easily and to ensure that patients receive an exact dose of Selegiline Hydrochloride, which is crucial for its effectiveness and safety. Selegiline is a selective monoamine oxidase inhibitor (MAOI), specifically inhibiting the enzyme monoamine oxidase type B (MAO-B). This enzyme is responsible for the breakdown of dopamine in the brain. By inhibiting MAO-B, Selegiline increases the levels of dopamine, which can help alleviate symptoms associated with Parkinson's disease and major depressive disorder.

In the treatment of Parkinson's disease, Selegiline is often used as an adjunct to levodopa/carbidopa therapy. It can help to enhance and prolong the effects of levodopa, which may lead to an improvement in the control of motor fluctuations and a reduction in 'off' periods during which the medication's effects wear off and symptoms return. For depression, Selegiline's MAO-B inhibiting action can also lead to an increase in the levels of other neurotransmitters, such as phenethylamine and possibly serotonin and norepinephrine, which may contribute to its antidepressant effects.

It is important for patients and prescribers to be aware that Selegiline may interact with certain medications, including other antidepressants, and can have contraindications in certain medical conditions. Dietary restrictions may also be necessary to avoid hypertensive crises when higher doses are used, although at the 1.25 mg dosage, these restrictions are typically not required. Monitoring for side effects, such as orthostatic hypotension, insomnia, or confusion, is also important. As with any medication, adherence to prescribed dosing schedules is essential for optimal outcomes.

For those considering Selegiline HCl 1.25 mg Oral Capsules, it is crucial to consult with a healthcare provider to determine if this medication is appropriate for your specific condition and to discuss any potential interactions with other medications you may be taking. If you have any questions or require further information about this formulation, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is dedicated to providing you with the necessary support and guidance to ensure safe and effective treatment with Selegiline HCl.

Selegiline HCl (hydrochloride) is a monoamine oxidase inhibitor (MAOI) that is primarily used to treat Parkinson's disease and, in some cases, major depressive disorder. It works by inhibiting the enzyme monoamine oxidase type B (MAO-B), which breaks down dopamine in the brain, thereby increasing the levels of dopamine and helping to improve motor symptoms in Parkinson's disease. When used for depression, it inhibits MAO-A and MAO-B to varying degrees, depending on the dose, which can lead to increased levels of neurotransmitters such as serotonin and norepinephrine.

When considering the use of Selegiline HCl 1.25 mg oral capsules, it is crucial to be aware of potential drug interactions that can lead to serious adverse effects or reduced therapeutic efficacy. Selegiline should not be used concomitantly with other MAOIs, as this can lead to a hypertensive crisis or serotonin syndrome, a potentially life-threatening condition. Additionally, the use of Selegiline with serotonergic drugs, such as SSRIs, SNRIs, tricyclic antidepressants, or St. John's Wort, should be approached with caution and may require a washout period to avoid serotonin syndrome.

Patients should also avoid the use of sympathomimetic amines, including over-the-counter cold, allergy, and cough medications containing ephedrine or pseudoephedrine, as these can lead to hypertensive reactions when taken with Selegiline. The use of opioid medications, particularly meperidine, tramadol, methadone, and propoxyphene, should be avoided due to the risk of serious and potentially fatal reactions. Additionally, Selegiline can potentiate the effects of levodopa and may require a reduction in levodopa dosage to avoid exacerbating dopaminergic side effects such as dyskinesias.

Patients should also be advised to avoid foods and beverages high in tyramine, as Selegiline can inhibit MAO-A at higher doses, leading to the risk of hypertensive crisis when tyramine-containing foods are consumed. Foods to avoid include aged cheeses, cured meats, fermented products, soy sauce, tap beers, and red wine. Furthermore, antihypertensive medications may require dosage adjustments due to potential additive hypotensive effects when used with Selegiline.

It is important to inform healthcare providers of all medications, supplements, and herbal products being taken before starting Selegiline to avoid harmful interactions. Patients should be monitored closely for any adverse reactions, especially when initiating or discontinuing drugs that may interact with Selegiline. If you have any questions or concerns regarding the use of Selegiline HCl 1.25 mg oral capsules or potential drug interactions, please reach out to us at Bayview Pharmacy for further assistance.

Selegiline HCl (hydrochloride) is an oral medication that belongs to a class of drugs known as monoamine oxidase inhibitors (MAOIs). Specifically, selegiline is a selective inhibitor of monoamine oxidase type B (MAO-B). This enzyme is responsible for the breakdown of dopamine, a neurotransmitter that plays a key role in motivation, pleasure, and motor control. By inhibiting MAO-B, selegiline increases the levels of dopamine in the brain, which can help to alleviate symptoms associated with Parkinson's disease and major depressive disorder.

In the treatment of Parkinson's disease, selegiline is used as an adjunct to levodopa/carbidopa therapy. It can help to enhance and prolong the effects of levodopa, which is the precursor to dopamine and is commonly used to treat Parkinson's symptoms. By increasing dopamine levels, selegiline can help to improve motor function and reduce the 'wearing-off' effect that some patients experience as the effects of levodopa diminish. It is important to note that selegiline is not a cure for Parkinson's disease, but it can help to manage symptoms and improve quality of life for patients.

For the treatment of major depressive disorder, selegiline in higher doses has been shown to have antidepressant properties. It is thought that the increase in dopamine, as well as other neurotransmitters like serotonin and norepinephrine, can help to alleviate depressive symptoms. However, the 1.25 mg dosage of selegiline is typically used for Parkinson's disease, and higher doses would be required for the treatment of depression.

The selegiline HCl 1.25 mg oral capsules provided by Bayview Pharmacy are a solid dosage form consisting of two gelatin or vegetarian shells that enclose the medication. These capsules are designed to be swallowed whole, releasing the selegiline in the stomach where it is absorbed into the bloodstream. The capsule form ensures a precise dosage of the active ingredient, which is crucial for maintaining the desired therapeutic effect while minimizing the risk of side effects. Additionally, the encapsulated form of the medication can help to protect the active ingredient from degradation and improve its shelf life.

It is important for patients and prescribers to be aware of potential interactions with other medications and substances when using selegiline. For example, combining selegiline with certain antidepressants or consuming foods high in tyramine can lead to serious side effects. Therefore, it is essential to follow the guidance of a healthcare professional when using this medication.

If you have any questions about the selegiline HCl 1.25 mg oral capsules or how they work in treating Parkinson's disease or other conditions, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide you with the information and support you need to ensure safe and effective treatment.

Selegiline HCl, most commonly used in the management of Parkinson's disease, can also have off-label uses that may extend beyond its conventional application in neurology. As a selective monoamine oxidase inhibitor (MAOI), selegiline has been investigated for use in patients with treatment-resistant depression, as it can enhance the effects of neurotransmitters in the brain, potentially providing relief when other antidepressants have failed. Furthermore, some studies suggest that selegiline could have neuroprotective effects that might be beneficial in other neurodegenerative disorders due to its ability to inhibit the breakdown of dopamine, a key neurotransmitter. Additionally, it has been explored in the treatment of Alzheimer's disease for its potential to improve cognitive functions, though its efficacy in this area remains a subject for ongoing research.

Another intriguing area of use is in the treatment of attention deficit hyperactivity disorder (ADHD), where selegiline's influence on dopamine and attention regulation may offer some therapeutic benefits. Moreover, the medication has been evaluated as a possible adjunct therapy in smoking cessation programs, capitalizing on its dopaminergic activity to mitigate the effects of nicotine withdrawal. It's also worth noting that selegiline has been used in veterinary medicine, particularly for treating canine cognitive dysfunction (a condition analogous to Alzheimer's in humans) and Cushing's disease in dogs.

It is important for prescribers and patients to note that while selegiline has various potential applications, many of these other uses are considered 'off-label' and have not been approved by regulatory agencies such as the FDA. Therefore, these treatments should be approached with careful consideration and under the guidance of a healthcare professional. The set dosage form, Selegiline HCl 1.25 mg Oral Capsules, provides a precise and controlled amount of medication, which is beneficial for exploring these alternative uses when dosage management is crucial. As with any medication, the risk-to-benefit ratio must be evaluated on an individual basis, and monitoring for adverse interactions with other medications is essential, especially given selegiline's MAOI activity. If there are any questions or a need for further clarification regarding the uses of Selegiline HCl 1.25 mg Oral Capsules, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide comprehensive support to both patients and prescribers.